HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Oncogenic stress sensitizes murine cancers to hypomorphic suppression of ATR.

Abstract
Oncogenic Ras and p53 loss-of-function mutations are common in many advanced sporadic malignancies and together predict a limited responsiveness to conventional chemotherapy. Notably, studies in cultured cells have indicated that each of these genetic alterations creates a selective sensitivity to ataxia telangiectasia and Rad3-related (ATR) pathway inhibition. Here, we describe a genetic system to conditionally reduce ATR expression to 10% of normal levels in adult mice to compare the impact of this suppression on normal tissues and cancers in vivo. Hypomorphic suppression of ATR minimally affected normal bone marrow and intestinal homeostasis, indicating that this level of ATR expression was sufficient for highly proliferative adult tissues. In contrast, hypomorphic ATR reduction potently inhibited the growth of both p53-deficient fibrosarcomas expressing H-rasG12V and acute myeloid leukemias (AMLs) driven by MLL-ENL and N-rasG12D. Notably, DNA damage increased in a greater-than-additive fashion upon combining ATR suppression with oncogenic stress (H-rasG12V, K-rasG12D, or c-Myc overexpression), indicating that this cooperative genome-destabilizing interaction may contribute to tumor selectivity in vivo. This toxic interaction between ATR suppression and oncogenic stress occurred without regard to p53 status. These studies define a level of ATR pathway inhibition in which the growth of malignancies harboring oncogenic mutations can be suppressed with minimal impact on normal tissue homeostasis, highlighting ATR inhibition as a promising therapeutic strategy.
AuthorsDavid W Schoppy, Ryan L Ragland, Oren Gilad, Nishita Shastri, Ashley A Peters, Matilde Murga, Oscar Fernandez-Capetillo, J Alan Diehl, Eric J Brown
JournalThe Journal of clinical investigation (J Clin Invest) Vol. 122 Issue 1 Pg. 241-52 (Jan 2012) ISSN: 1558-8238 [Electronic] United States
PMID22133876 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)
Chemical References
  • Cell Cycle Proteins
  • RNA, Messenger
  • Atr protein, mouse
  • ATR protein, human
  • Ataxia Telangiectasia Mutated Proteins
  • Protein Serine-Threonine Kinases
Topics
  • Animals
  • Ataxia Telangiectasia Mutated Proteins
  • Cell Cycle Proteins (antagonists & inhibitors, genetics)
  • DNA Damage
  • Fibrosarcoma (genetics, therapy)
  • Genes, p53
  • Genes, ras
  • Homeostasis
  • Humans
  • Leukemia, Myeloid, Acute (genetics, therapy)
  • Mice
  • Mice, 129 Strain
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Mice, Nude
  • Mice, Transgenic
  • Mutation
  • Neoplasms, Experimental (genetics, pathology, therapy)
  • Oncogenes
  • Protein Serine-Threonine Kinases (antagonists & inhibitors, genetics)
  • RNA, Messenger (genetics, metabolism)
  • Stress, Physiological

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: